期刊
NEUROPSYCHIATRIC DISEASE AND TREATMENT
卷 16, 期 -, 页码 2689-2693出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/NDT.S277392
关键词
major depressive disorder; exosome; miR-139-5p; biomarker
资金
- National Natural Science Foundation of China [82071676, 81703492]
- Beijing Natural Science Foundation [7182092]
- High-Level Hospital Development Program for Foshan Climbing Project
Background: MicroRNAs (miRs) have been suggested to be biomarkers to inform the diagnosis of major depressive disorder (MDD). We have previously shown that exosomederived miR-139-5p had potential in differentiating between patients with MDD and healthy control (HC) subjects. Materials and Methods: To validate the potential of exosome-derived miR-139-5p as a biomarker for MDD, here we recruited 30 patients with MDD and 30 HC subjects, and used TaqMan probes to detect serum exosomal miR-139-5p levels. Results: The data showed that patients with MDD had significantly increased exosomal miR-139-5p levels when compared with controls. Correlation analysis suggested that sex, age, and body mass index did not significantly affect blood exosomal miR-139-5p levels in the tested subjects. The ROC curve showed that serum-derived miR-139-5p had reasonable performance in discriminating patients with MDD and HC subjects, with a sensitivity of 0.867 and specificity of 0.767, and the AUC was 0.807. Discussion: Taken together, these results demonstrated that patients with MDD were accompanied by significantly increased blood exosomal miR-139-5p levels, and exosomal miR-139-5p is a promising biomarker for the diagnosis of MDD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据